Novo Nordisk’s CagriSema Misses Non‑Inferiority Goal but Delivers 23% Weight Loss in REDEFINE 4 Trial
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novo Nordisk ( (NVO) ) has issued an update.
On 23 February 2026, Novo Nordisk reported headline phase 3 data from its REDEFINE 4 obesity trial, showing that once-weekly CagriSema, a fixed-dose combination of cagrilintide and semaglutide, led to 23% weight loss at 84 weeks in people with obesity and comorbidities but failed to meet the primary endpoint of non-inferiority versus Eli Lilly’s rival drug tirzepatide, which achieved greater weight loss. CagriSema showed a safety and tolerability profile consistent with the GLP‑1 class, and despite the setback, Novo Nordisk is pressing ahead with its obesity franchise, pointing to an ongoing FDA review based on other pivotal trials, additional phase 3 studies such as REDEFINE 11, and a planned higher-dose programme, underscoring the company’s strategic push to defend and extend its leadership in the fast-growing obesity-treatment market.
The REDEFINE 4 results underline both the competitive pressure from tirzepatide and the potential of CagriSema as a first-in-class GLP‑1/amylin combination that may provide additive weight-loss benefits over GLP‑1 monotherapy if higher or optimised doses prove more effective. For patients and investors, the data suggest that while CagriSema’s initial dose may not match the strongest competitor on weight loss, Novo Nordisk still sees a path to meaningful clinical and commercial impact through label-seeking trials, cardiovascular outcomes studies and future dose escalations that could sustain its position in obesity care.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a historical focus on diabetes and other serious chronic diseases. The group develops and markets innovative treatments, including GLP‑1‑based therapies for diabetes and obesity, employs about 68,800 people in 80 countries, and sells its products in roughly 170 markets worldwide.
Average Trading Volume: 21,464,309
Technical Sentiment Signal: Sell
Current Market Cap: $217.7B
Learn more about NVO stock on TipRanks’ Stock Analysis page.
